Kiora Pharmaceuticals Investor Presentation — March 2021

Document content

THE OPHTHALMOLOGY MEDICINES COMPANY

Healthcare Conference

M arch 10, 2 02 12

These slides contain forward -looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “cou ld,” “expect,”

“plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar exp ressions are intended to

identify forward -looking statements. Forward -looking statements include statements regarding our 2022 Vision; our ability to sub mit a BLA for

KSI-301 in wet AMD, DME, RVO and potentially diabetic retinopathy in 2022; the potential licensure of KSI -301 in the U.S. and EU in 2023; our

platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing ther eof; the

anticipated design of our clinical trials and regulatory submissions; expectations regarding the potential efficacy and comme rcial prospects of

our product candidates; the anticipated presentation of additional data; the results of our research and development efforts; and our ability to

advance our product candidates into later stages of development and potential commercialization. All forward -looking statements are based on

management’s current expectations, and future events are subject to a number of risks and uncertainties that could cause actual results to

differ materially and adversely from those set forth or implied by such forward -looking statements. These risks and uncertainti es include, but

are not limited to, the safety, efficacy and durability data for our KSI -301 product candidate may not continue or persist; cess ation or delay of any

of the ongoing clinical studies and/or our development of KSI -301 may occur, including as a result of the ongoing COVID -19 pande mic; future

potential regulatory milestones of KSI -301, including those related to current and planned clinical studies may be insufficient to support

regulatory submissions or approval; anticipated presentation of data at upcoming conferences may not occur; our research and development

efforts and our ability to advance our product candidates into later stages of development may fail; any one or more of our p roduct candidates

may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets,

including the ongoing COVID -19 pandemic, which may significantly impact our business and operations, including out of our headqu arters in

the San Francisco Bay Area and our clinical trial sites, as well as the business or operations of our manufacturers, contract research organizations